Cambridge Equities, LP - Nov 10, 2025 SCHEDULE 13D/A Report for ImmunityBio, Inc. Common Stock, par value $0.0001 per share (IBRX)

Filing Manager
Cambridge Equities, LP
Reporting Manager
Patrick Soon-Shiong
Security
ImmunityBio, Inc. Common Stock, par value $0.0001 per share
Symbol
IBRX
Shares outstanding
1.08B shares
Disclosed Ownership
744M shares
Ownership
68.9%
Form type
SCHEDULE 13D/A
Date filed
11/10/2025, 07:43 PM
Date of event
Nov 10, 2025
SEC
View on sec.gov

Reporting Managers (7)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Cambridge Equities, LP 26.6% 262M 0 262M /s/ Charles Kenworthy Charles Kenworthy, Manager of MP 13 Ventures, LLC, the General Partner of Cambridge Equities, LP 0001629222
MP 13 Ventures, LLC 26.6% 262M 0 262M /s/ Charles Kenworthy Charles Kenworthy, Manager 0001629186
NantWorks, LLC 10% 98.5M 0 98.5M /s/ Robert Morse Robert Morse, CFO of NantWorks, LLC 0001675760
NantMobile, LLC 4.8% 47.6M 0 47.6M /s/ Robert Morse Robert Morse, CFO of NantMobile, LLC 0001567221
Nant Capital, LLC 31.5% 339M 0 339M /s/ Charles Kenworthy Charles Kenworthy, Manager of Nant Capital, LLC 0001675758
California Capital Equity, LLC 10.8% 107M 0 107M /s/ Charles Kenworthy Charles Kenworthy, Manager of California Capital Equity, LLC 0001517764
Patrick Soon-Shiong 68.9% 744M 30.7M 713M /s/ Patrick Soon-Shiong Patrick Soon-Shiong 0001189020